Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and <or=50 copies/mL, respectively. Mutations remained detectable for at least 48 weeks in some subjects.
Dept of Medicine, University of California, San Francisco, CA 94110, USA. chare@php.ucsf.edu
C Bradley
CB
Hare
John
J
Mellors
Amy
A
Krambrink
Zhaohui
Z
Su
Daniel
D
Skiest
David M
DM
Margolis
Sheran S
SS
Patel
Douglas
D
Barnas
Lisa
L
Frenkel
Robert W
RW
Coombs
Francesca
F
Aweeka
Gene D
GD
Morse
David W
DW
Haas
Valerie
V
Boltz
Sarah
S
Palmer
John
J
Coffin
Diane V
DV
Havlir
D000328:Adult; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D019562:Viral Load
D018894:Reverse Transcriptase Inhibitors